CTS-21166
CTS-21166 is a blood-brain barrier-permeable and orally active BACE1 inhibitor. CTS-21166 reduces brain Aβ levels. CTS-21166 can be used in the research of Alzheimer's disease[1][2].
Product Specifications
CAS Number
1226777-95-2
UNSPSC
12352005
Target
Amyloid-β; Beta-secretase
Related Pathways
Neuronal Signaling
Field of Research
Neurological Disease
Smiles
O=C(C1=CC(N(C)S(=O)(C)=O)=CC(C(N[C@@H](C)[C@@H](C)C[C@@H](C)C(N[C@H](C(NC(C)C)=O)C(C)C)=O)=O)=C1)N[C@@H](C2=CC=CC=C2)C
Molecular Formula
C34H51N5O6S
Molecular Weight
657.86
References & Citations
[1]Yan R. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016 Jul 14;5:13. |[2]Menting KW, et al. β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. Front Aging Neurosci. 2014 Jul 21;6:165.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
BACE1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC682716-500 1x 500 µL
PAPP-A / Pappalysin-1 (Marker of Atherosclerosis and Aneuploid Fetus) (PAPPA/2716), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
I7661-88A 10 KU
Interferon alpha, Recombinant, Mouse (IFNa14-16) discontinued
Sign In for Pricing
View Details